Arrowstreet Capital, Limited Partnership Denali Therapeutics Inc. Transaction History

Arrowstreet Capital, Limited Partnership

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $486,288 - $721,474	18,725 New	18,725 $575,000
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $4.13 Million - $5.33 Million	-96,868 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $4.7 Million - $7.58 Million	96,868 New	96,868 $4.89 Million
Q2 2021 Aug 13, 2021	SELL	$50.3 - $78.44 $4.31 Million - $6.72 Million	-85,607 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$53.8 - $81.53 $2.38 Million - $3.61 Million	-44,232 Reduced 34.07%	85,607 $4.89 Million
Q4 2020 Feb 12, 2021	BUY	$36.89 - $93.56 $2.74 Million - $6.96 Million	74,368 Added 134.07%	129,839 $10.9 Million
Q3 2020 Nov 12, 2020	BUY	$23.13 - $38.84 $1.28 Million - $2.15 Million	55,471 New	55,471 $1.99 Million
Q1 2020 May 15, 2020	SELL	$14.2 - $27.98 $472,036 - $930,111	-33,242 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$14.4 - $19.99 $478,684 - $664,507	33,242 New	33,242 $579,000
Q2 2019 Aug 14, 2019	SELL	$18.5 - $28.14 $931,160 - $1.42 Million	-50,333 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$17.99 - $24.65 $905,490 - $1.24 Million	50,333 New	50,333 $1.17 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.